Infectious Disease Molecular Diagnostics
APAC · 2 shared keywords
Updated
Reviewed by Vidhi Upadhyay
APAC Point-of-Care Molecular Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Technology, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.50 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $795.5 Mn | — | — |
| 2025 (base) | $887.8 Mn | +$92.3 Mn | — |
| 2026 (forecast) | $990.7 Mn | +$103.0 Mn | +11.6% |
| 2027 (forecast) | $1.11 Bn | +$114.9 Mn | +24.5% |
| 2028 (forecast) | $1.23 Bn | +$128.3 Mn | +39% |
| 2029 (forecast) | $1.38 Bn | +$143.1 Mn | +55.1% |
| 2030 (forecast) | $1.54 Bn | +$159.7 Mn | +73.1% |
| 2031 (forecast) | $1.72 Bn | +$178.3 Mn | +93.2% |
| 2032 (forecast) | $1.91 Bn | +$198.9 Mn | +115.6% |
| 2033 (forecast) | $2.14 Bn | +$222.0 Mn | +140.6% |
| 2034 (forecast) | $2.38 Bn | +$247.8 Mn | +168.5% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $887.8 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.38 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 11.6% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Test, technology and end user (see all) |
| Key players | Cepheid, Abbott Laboratories, Roche Diagnostics, bioMérieux SA, Visby Medical (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Point-of-care molecular diagnostics run PCR and similar DNA tests near the patient, giving lab-quality results in minutes.
Key segments of the point-of-Care Molecular Diagnostics market include test (Respiratory Infections, Sexually Transmitted Infections and Hospital Infections) and technology (PCR and Isothermal Amplification).
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the point-of-Care Molecular Diagnostics market.
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the point-of-Care Molecular Diagnostics market room to grow, especially in emerging markets.
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the point-of-Care Molecular Diagnostics market.
The point-of-Care Molecular Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, medical devices are regulated by TGA (Australia)[1], NMPA (China)[2], MDACS (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], MDA (Malaysia)[6], Medsafe (WAND) (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], Ministry of Health (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Ministry of Health (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Medical Device Division, Department of Health. Checked 14 Nov 2026.
[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.
[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[6] Medical Device Authority. Checked 14 Nov 2026.
[7] Medsafe. Checked 14 Nov 2026.
[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.
[9] Health Sciences Authority. Checked 14 Nov 2026.
[10] Thai Food and Drug Administration. Checked 14 Nov 2026.
[11] Ministry of Health of Indonesia. Checked 19 Nov 2026.
[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.
[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.
[14] Ministry of Health of Vietnam. Checked 19 Nov 2026.
[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[16] National Healthcare Security Administration. Checked 14 Nov 2026.
[17] Hospital Authority. Checked 14 Nov 2026.
[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[20] Ministry of Health Malaysia. Checked 14 Nov 2026.
[21] Pharmac. Checked 14 Nov 2026.
[22] PhilHealth. Checked 14 Nov 2026.
[23] CPF Board, MediShield Life. Checked 14 Nov 2026.
[24] National Health Security Office. Checked 14 Nov 2026.
[25] BPJS Kesehatan. Checked 19 Nov 2026.
[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.
[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.
[28] Vietnam Social Security. Checked 19 Nov 2026.
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how point-of-Care Molecular Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in APAC.
What doctors and scientists are doing in Point-of-Care Molecular Diagnostics right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
APAC · 2 shared keywords
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC · 1 shared keyword
APAC
APAC
Digital Health · APAC
Healthcare Services · APAC
Healthcare Services · APAC
Pharmaceuticals · APAC
Healthcare Services · APAC
Healthcare Services · APAC